Can a school-based trauma program keep incarcerated teens from turning to drugs?

NCT ID NCT07682441

Not yet recruiting Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This pilot study tests a behavioral program called CBITS-RTM, adapted for teens in juvenile detention. The program combines group and individual therapy to address post-traumatic stress and includes a module on racial trauma. Researchers want to see if it reduces PTSD symptoms and lowers the risk of substance use after the teens are released.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adapted Cognitive Behavioral Intervention for Trauma in Schools with a Racial Trauma Module (CBITS-RTM)
What this could lead to: If effective, this program could offer a practical way to reduce PTSD and substance use in a high-risk, underserved youth population.
What could go wrong: This is a small pilot study with only 28 participants, so results may not apply broadly. The intervention requires several months to complete, which may limit feasibility.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PTSD - POST TRAUMATIC STRESS DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

combat disorder post-traumatic stress disorder substance abuse substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PTSD - POST TRAUMATIC STRESS DISORDER SUBSTANCE USE

Contacts and locations

Locations

UCSF Zuckerberg San Francisco General Hospital

San Francisco, California, 94131, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.